ARTICLE | Finance
With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year
January 14, 2021 2:05 AM UTC
IO Biotech parlayed early clinical data into a €127 million ($154.8 million) series B financing led by HBM Healthcare Investments, which will support a Phase II trial of its leading cancer vaccines in combination with checkpoint inhibitors.
The deal marks the second-largest venture round for a European biotech over the last 12 months, behind the €560 million round CureVac N.V. (NASDAQ:CVAC) closed in July ahead of its August IPO. ...